Question 1

How does SURMOUNT-2 differ from SURPASS-2?

Accepted Answer

SURPASS-2 (Frías 2021, NEJM, PMID 34170647) was the registrational tirzepatide trial for type 2 diabetes itself — it tested 5 mg, 10 mg, and 15 mg of tirzepatide against semaglutide 1 mg in 1,879 adults with T2D on metformin, and was powered around HbA1c reduction as the primary endpoint. SURMOUNT-2 (Garvey 2023, Lancet, PMID 37385275) was the obesity-focused trial in adults with T2D — it tested only the higher 10 mg and 15 mg doses against placebo in 938 participants, was powered around percent weight loss as the primary endpoint, and ran 72 weeks instead of SURPASS-2's 40 weeks. The two trials together supported Mounjaro's T2D label and Zepbound's obesity-plus-T2D label using the same molecule under two different brand names.

Question 2

Why is weight loss lower in T2D than in non-diabetic adults?

Accepted Answer

Tirzepatide 15 mg produced 14.7% mean weight loss in SURMOUNT-2 versus 20.9% in SURMOUNT-1's non-diabetic population — a gap of about 6 percentage points. The same blunting pattern was seen with semaglutide: STEP-1 reported 14.9% in non-diabetic adults but STEP-2 reported only 9.6% in adults with T2D. The reasons are partially understood and probably multifactorial: people with T2D often have a longer history of weight regulation dysfunction, take diabetes medications (some insulin-sensitizers and certainly insulin itself) that promote weight retention, may have impaired postprandial GLP-1 secretion at baseline, and show somewhat reduced incretin responsiveness on the central side. The clinically relevant message is that the diabetes blunting affects all incretin drugs, the absolute weight loss is still very large versus any prior obesity drug, and the 14.7% figure was achieved on top of background diabetes therapy that was held constant.

Question 3

Should a patient with obesity plus T2D pick Mounjaro or Zepbound?

Accepted Answer

Mounjaro and Zepbound are the same molecule (tirzepatide) made by Eli Lilly under two different brand labels. Mounjaro carries the FDA T2D label with approved doses from 2.5 mg up to 15 mg, while Zepbound carries the FDA obesity / chronic weight management label at 5 mg, 10 mg, and 15 mg. SURMOUNT-2 specifically tested 10 mg and 15 mg in adults with T2D and obesity, so those doses are the evidence-backed weight-loss range. In practice the choice is usually driven by insurance: many commercial plans cover Mounjaro for T2D under medical necessity but exclude obesity drugs entirely, in which case Mounjaro is the only path to the molecule. Where both are covered, Zepbound is typically used because its label maps cleanly to the SURMOUNT-2 dosing the trial actually tested.

Question 4

Was hypoglycemia a common problem in SURMOUNT-2?

Accepted Answer

No — clinically significant hypoglycemia (glucose under 54 mg/dL) was rare across all three arms, and the Garvey 2023 publication reported no severe (level 3) hypoglycemia. Two design choices kept the rate low: insulin users were excluded outright, and sulfonylureas were not allowed as background therapy. Because tirzepatide itself does not directly stimulate insulin release in a glucose-independent way, the on-drug hypoglycemia risk is small in patients not also taking insulin or sulfonylureas. In real-world practice the relevant clinical caution is exactly the inverse of the trial population: patients on insulin or sulfonylureas should generally have those doses reduced when starting tirzepatide, because the substantial drop in glucose that tirzepatide itself causes can unmask hypoglycemia from the background agent.

Question 5

How does SURMOUNT-2 compare to STEP-2?

Accepted Answer

STEP-2 (Davies 2021, Lancet, PMID 33667417) was the semaglutide-in-obesity-plus-T2D trial: 1,210 adults with BMI ≥27 and T2D, randomized to semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo for 68 weeks. Mean weight loss with semaglutide 2.4 mg was 9.6% vs 3.4% on placebo, with HbA1c reduction of about 1.6 percentage points. SURMOUNT-2 used tirzepatide 10 mg and 15 mg over 72 weeks and reported 12.8% and 14.7% weight loss and ~2.2-point HbA1c reductions — meaningfully larger on both axes. The trials were not head-to-head and populations differed slightly (SURMOUNT-2 had a higher baseline HbA1c around 8.0% versus around 8.1% in STEP-2 — broadly similar). The pattern matches the broader tirzepatide-vs-semaglutide head-to-head seen later in SURMOUNT-5 (obesity, no diabetes) and SURPASS-2 (T2D, head-to-head): tirzepatide produces roughly 5 to 7 percentage points more weight loss at matched durations.

Question 6

Why did SURMOUNT-2 only test 10 mg and 15 mg, not 5 mg?

Accepted Answer

SURMOUNT-1 had tested all three approved obesity doses (5 mg, 10 mg, 15 mg) and demonstrated a monotonic dose response without diabetes. For the diabetes population, Eli Lilly elected to study only the two higher doses because the SURPASS T2D program had already characterized the 5-mg dose extensively for glycemic effect and a smaller dose was less likely to deliver weight-loss-grade effect in a population with diabetes-related blunting. The trial design prioritized statistical power on the harder question — does tirzepatide produce obesity-grade weight loss when diabetes is on board — and the answer at 10 mg and 15 mg was a clear yes. In clinical practice, 5 mg is still routinely used as a starting / escalation dose for tolerability in patients with T2D before titrating up to the SURMOUNT-2-tested 10 mg or 15 mg.

Endpoint	Treatment	Comparator	Difference
Proportion achieving ≥5% body-weight reduction at week 72 (coprimary) More than four of five tirzepatide participants reached the conventional clinical threshold for meaningful weight loss despite concurrent T2D.	10 mg: 81.6%; 15 mg: 86.4%	30.6%	Odds ratio favored both tirzepatide doses; P<0.0001
Proportion achieving ≥10% body-weight reduction at week 72 Roughly two-thirds of participants on either tirzepatide dose hit ≥10%, a threshold typically associated with regression of fatty-liver disease and meaningful cardiometabolic improvement.	10 mg: 63.4%; 15 mg: 69.6%	8.7%	P<0.0001 for both doses
Proportion achieving ≥15% body-weight reduction at week 72 Over half of 15-mg participants reached a magnitude long associated only with bariatric surgery — and did so with T2D on board.	10 mg: 41.4%; 15 mg: 51.8%	2.6%	P<0.0001 for both doses
Proportion achieving ≥20% body-weight reduction at week 72	10 mg: 23.0%; 15 mg: 34.0%	1.0%	P<0.0001 for both doses
HbA1c change from baseline at week 72 (percentage points) From a mean baseline HbA1c of 8.02%, both tirzepatide doses brought participants into the mid-5% range on average — the largest A1c reduction reported in any phase-3 obesity-plus-T2D trial.	10 mg: -2.14; 15 mg: -2.22	-0.16	Placebo-subtracted -1.98 percentage points at 10 mg and -2.06 at 15 mg
Proportion achieving HbA1c <7% at week 72 Roughly nine of ten tirzepatide participants reached the standard ADA glycemic goal — versus fewer than three in ten on placebo plus lifestyle.	10 mg: 90.0%; 15 mg: 90.7%	29.3%	P<0.0001 for both doses
Change in waist circumference at week 72 (cm)	10 mg: -11.2 cm; 15 mg: -13.8 cm	-3.4 cm	Placebo-subtracted -7.8 cm at 10 mg and -10.4 cm at 15 mg
Change in fasting serum glucose at week 72 (mg/dL)	10 mg: -49.2 mg/dL; 15 mg: -51.7 mg/dL	-2.4 mg/dL	Placebo-subtracted -46.8 mg/dL at 10 mg and -49.3 mg/dL at 15 mg
Change in systolic blood pressure at week 72 (pooled tirzepatide doses, mmHg) Magnitude comparable to a low-dose antihypertensive added to standard care.	-7.2 mmHg	-1.0 mmHg	Placebo-subtracted -6.2 mmHg
Percent change in triglycerides at week 72 (pooled tirzepatide doses)	-28.6%	-5.8%	Placebo-subtracted -22.8 percentage points
Percent change in HDL cholesterol at week 72 (pooled tirzepatide doses)	+8.2%	+1.1%	—
Percent change in LDL cholesterol at week 72 (pooled tirzepatide doses) Smaller LDL rise on tirzepatide than placebo; both arms saw modest increases.	+2.7%	+6.3%	—

Event	Treatment rate	Comparator rate
Gastrointestinal disorders (any) Per Garvey 2023, gastrointestinal events were mostly mild to moderate; clustered during the 20-week dose-escalation phase.	10 mg and 15 mg pooled: most-common AE class; nausea, diarrhea, and vomiting predominated	Substantially lower on placebo
Discontinuation of study drug due to adverse events Per the publication, few events led to treatment discontinuation despite the GI burden.	Under 5% across both tirzepatide arms	Similar low rate on placebo
Serious adverse events (any) No concentration in any single organ system; SAE rates broadly similar across arms per the ClinicalTrials.gov posting.	10 mg: 5.8% (18/312); 15 mg: 8.7% (27/311)	7.3% (23/315)
Acute pancreatitis (adjudicated) Numerically more on 15 mg but rare in absolute terms; consistent with the GLP-1 / dual-incretin class signal.	10 mg: 0 events; 15 mg: 2 events	0 events
Acute cholecystitis / gallbladder events Rates broadly balanced; cholelithiasis is a known consequence of rapid weight loss.	15 mg: 2 events	2 events
Clinically significant hypoglycemia (glucose <54 mg/dL) Hypoglycemia was infrequent in SURMOUNT-2 because insulin and sulfonylurea users were excluded; per the publication no severe (level 3) hypoglycemia was observed.	Rare across both tirzepatide doses	Rare on placebo
Deaths Both deaths in the 10-mg arm were adjudicated as unrelated to study drug per Garvey 2023.	10 mg: 2; 15 mg: 0	0

SURMOUNT-2 deep dive: tirzepatide 10/15 mg in obesity plus type 2 diabetes

Primary endpoint

Secondary endpoints

Adverse events

Subgroup analyses

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives